The TA-125 Index, typically referred to as the Tel Aviv 125 and formerly the TA-100 Index, is a stock market index of the 125 most highly capitalised companies listed on the Tel Aviv Stock Exchange (TASE). The index began on 1 January 1992 with a base level of 100. The highest value reached to date is 2152.16, in January 2022. On 12 February 2017, the index was expanded to include 125 instead of 100 stocks, in an attempt to improve stability and therefore reduce risk for trackers and encourage foreign investment.
36-584: NFTA may refer to: Naphtha Explorations Limited Partnership, ticker symbol in the TA-100 Israeli stockmarket index Niagara Frontier Transportation Authority , responsible for public transportation oversight of Erie and Niagara counties in the state of New York Nondeterministic finite tree automaton, investigated in theoretical computer science and formal language theory, see Tree automaton#Definitions Northern Tasmanian Football Association (1886–1986) ,
72-705: A public company . In 1954, Teva received a Certificate Excellence in Training award from the Israeli President, Yitzhak Ben Zvi . In 1964, Teva partnered with Sintex, a company from Mexico, and Schering Plough . In 1964, Assia and Zori merged and in 1968 acquired a controlling stake in Teva. In 1976, the three companies merged into the modern-day Teva Pharmaceutical Industries Ltd. In 1980, Teva acquired Ikapharm, then Israel's second largest drug manufacturer. In 1980, Teva acquired Plantex . In 1982, Teva
108-444: A former Australian rules football competition Northern Tasmanian Football Association (formed 1996) , an Australian rules football competition Nuova ferrovia transalpina , Italian name of Switzerland's north–south rail tunnel project NRLA Topics referred to by the same term [REDACTED] This disambiguation page lists articles associated with the title NFTA . If an internal link led you here, you may wish to change
144-577: A fortnight after Mylan offered to buy Perrigo for $ 29 billion. Teva's offer for Mylan was contingent on Mylan abandoning its pursuit of Perrigo. Mylan stated in June 2015 that Teva's disclosure that it had a 1.35 percent stake in Mylan violated US antitrust rules. In October, the company acquired Mexico-based Representaciones e Investigaciones Medicas (Rimsa) for around $ 2.3 billion. In the same month Teva acquired Gecko Health Innovations . In November 2015,
180-513: A further 42 products to Australian generics company, Mayne Pharma , for $ 652 million; the deal moved Mayne up 50 spots, into the top-25 companies of US generic companies. As part of the deal Teva will seek to raise $ 20 to $ 25 billion through a bond sale. After completing the $ 39 billion acquisition of Actavis Generics, Teva announced another, smaller, deal with Allergan, agreeing to acquire its generic distribution business Anda for $ 500 million. On October 21, 2011, Par Pharmaceutical has sealed
216-459: A lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo ( deutetrabenazine ) which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia ; and Ajovy ( fremanezumab ), used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in
252-578: A major portion was in Europe and North America. On December 23, 2008, Teva acquired Barr Pharmaceuticals for $ 7.5 billion, making Barr and Pliva (which Barr bought earlier) part of Teva. On March 18, 2010, Teva said it planned to acquire German generic Ratiopharm for US$ 5 billion. The deal was completed in August 2010, significantly expanding Teva's European coverage. In May 2011, Teva bought Cephalon for US$ 6.8 billion. The same month, Teva announced
288-625: A portfolio of drugs from pharmaceutical giant Teva Pharmaceuticals last year for $ 845 million Australian dollars. In February 2018, Teva Pharmaceutical Industries Ltd has completed the sale of a portfolio of products within its global women's health business across contraception, fertility, menopause and osteoporosis for $ 703 million in cash to CVC Capital Partners Fund VI. Teva also agreed to sell its Plan B One-Step and its brands of emergency contraception to Foundation Consumer Healthcare for $ 675 million in cash. Combined annual net sales of these products were $ 140 million last year. It also sold Paragard to
324-519: A portfolio of generic drugs from Teva Pharmaceutical Industries for about $ 586 million. On July 29, Cipla an Indian pharmaceutical company bought three products from Teva. Indian pharmaceutical company, Aurobindo, was in the race to buy some Teva assets. In October 2016, Teva has sold off part of its UK and Ireland generic business to Indian pharmaceutical company Intas Pharma for 600 million pounds (5083 crore Indian rupees) in cash. In August 2016, Australia pharmaceutical company Mayne Pharmaceutical bought
360-462: A result, Teva dropped its pursuit of Mylan . In order for the deal to gain regulatory approval, Teva sold off a number of assets, including a portfolio of five generic drugs to Sagent Pharmaceuticals for $ 40 million, as well as a further eight medicines to Dr. Reddy's in a $ 350 million deal. Teva also sold a further 15 marketed generics, as well as three others that were close to market, for $ 586 million to Impax Laboratories . In July, Teva sold off
396-436: A total of $ 641 million. In July 2017, it was reported that Pascal Soriot , CEO of AstraZeneca since 2012, would become the next CEO of Teva, succeeding Erez Vigodman, however this was soon refuted. As of August 2017, the company has struggled to attract a new CEO, leading to mounting questions for the board. In August 2017, the board of directors announced a 75% cut in the dividend, reflecting declining profitability, and
SECTION 10
#1732782475472432-618: Is calculated in real-time during trading hours and published every 30 seconds. The index combines the companies that are listed in the TA-35 and TA-90 indices. The TA-35 Index is the TASE's flagship index. It was first published in 1992 under the name "MA'OF Index". The TA-35 index tracks the prices of the shares of the 35 companies with the highest market capitalization on the exchange. It serves as an underlying asset for options and futures, Index-Linked Certificates and Reverse Certificates traded on
468-482: Is floated as a percentage of issued shares. The free-float method, therefore, does not include restricted stocks, such as those held by company insiders. A company's weight in the index has an upper-limit of 9.8%, the weight of a company that should be higher is limited to 9.8% and the rest is divided between the other constituents of the index. Since October 2007 this restriction has set the effective weight of Teva Pharmaceutical Industries at 9.8%. To be included in
504-878: The British army present in the Middle East . After the war, Sir Alan Gordon Cunningham , the last of the High Commissioners for Palestine and Transjordan , visited Teva on behalf of the Secretary of State for the Colonies . His visit promoted Teva's reputation in the pharmaceutical market and created a momentum for Teva's development. During Mandatory Palestine , Teva exported its medical products to Arab countries. In 1941, Friedländer presented Teva products in an exhibition held in Cairo , Egypt . The exhibition
540-638: The 18th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. In 2023, Teva paid the largest fine to date for a domestic antitrust cartel in relation to a criminal investigation by the US Department of Justice into the company's price-fixing. Teva's earliest predecessor was SLE, Ltd., a wholesale drug business founded in 1901 in Ottoman Empire's Mutasarrifate of Jerusalem . SLE Ltd. took its name from
576-546: The Americas in Philadelphia, PA, and was considering opening its US headquarters in the area. In 2010, it had 39,660 employees. In Israel, the number of workers rose 7.5% by 6,774. In October 2010, Teva entered a licensing agreement with BioTime to develop and market BioTime's OpRegen for the treatment of age-related macular degeneration , an effort that in 2013 received $ 1.5 billion in funding from Israel's Office of
612-633: The Chief Scientist . In May 2011, Teva announced it would purchase Cephalon for US$ 6.8 billion. In January 2014, Teva acquired NuPathe , after outbidding Endo , for $ 144 million. In June 2014, Teva acquired Labrys Biologics for up to $ 825 million, the aim being to strengthen the company's migraine pipeline through addition of LBR-101, an anti- CGRP monoclonal antibody therapeutic . In March 2015, Teva acquired Auspex Pharmaceuticals for $ 3.5 billion growing its CNS portfolio. In April, Teva offered to acquire Mylan for $ 40 billion, only
648-805: The Israeli Government, from whom Teva received considerable tax breaks, and from Israel's labor federation, the Histadrut, Teva agreed to delay some of the layoffs in Israel. In October 2019, Teva faced criticism for making a “business decision to discontinue the drug” Vincristine , essential for the treatment of most childhood cancers according to the Food and Drug Administration. In July 2015, Allergan agreed to sell its generic drug business (Actavis Generics ) to Teva for $ 40.5 billion ($ 33.75 billion in cash and $ 6.75 billion worth of shares). As
684-627: The TA-125 index are promoted to the TA-35 index if their market capitalisation is 20% more than a current company. The following table shows the annual development of the TA-125 Index since 1993. TA-125 Index Components (as of 23 August 2020): As of 2023, research by "Calcalist" established a review on the state of gender representation among executive positions within the TA-125 listed companies. Out of 2,063 executive positions identified within these companies, 570 were held by women, 27.6% of
720-424: The TA-125 is calculated using a free float method, the total market capitalization of the companies weighted by their effect on the index, so the larger stocks would make more of a difference to the index as compared to a smaller market cap company. The basic formula for any index is (be it capitalization weighted or any other stock index). The Free float Adjustment factor represents the proportion of shares that
756-515: The TA-35 index the company's stock also need to adhere to the following requirement: Meet a public holding threshold of at least 25% and a minimal value of 600 million NIS (to ensure that there is a significant Free float holding, which is not controlled by insiders). The constituents of the indices are determined twice a year; on the first trading day in January and in July. The largest companies in
SECTION 20
#1732782475472792-689: The United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange . Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is
828-454: The company announced further divestments: a sale of contraception, fertility, menopause and osteoporosis products to CVC Capital Partners Fund VI for $ 703 million and its emergency contraception brands for $ 675 million to Foundation Consumer Healthcare . By December, the company had announced a drastic 25 percent workforce reduction (greater than 14,000 employees) as part of a two-year cost-reduction strategy. Following considerable lobbying by
864-418: The company announced it would collaborate with Heptares Therapeutics with its work on small-molecule calcitonin gene-related peptide antagonists for migraine treatment, with the deal generating up to $ 410 million. Teva Active Pharmaceutical Ingredients (TAPI) operates within Teva as a stand-alone business unit. In 2009, TAPI's sales to third parties totaled $ 565 million, and in 2010 sales rose by 13% to
900-859: The deal to three products from Teva Pharmaceutical Industries, which the Israeli firm was required by the US Federal Trade Commission to divest before it could acquire US biotech Cephalon for $ 6.8 billion. Following the acquisition of Allergan plc generic division some assets have been sold off to meet US antitrust requirements. In June 2016 Indian pharmaceutical company Dr. Reddy's Laboratories Ltd bought 8 (ANDA) Abbreviated New Drug Applications for $ 350 million in cash. Also in June 2016 Teva sold two ANDAs to Indian pharmaceutical company Zydus Cadilla, strengthening its US portfolio. On June 21, 2016, American pharmaceutical company Amneal Pharmaceutical previously known as Impax Laboratories bought
936-648: The exchange and worldwide. The index also began on 1 January 1992 with a base level of 100, and expanded from 25 to 35 stocks together with the TA-125 in February 2017. The TA-90 is a share index of the 90 most highly capitalised companies listed on the Tel Aviv Stock Exchange , which are not included in the TA-35 index. The index began in 1999 with a base level of 100. The index was expanded on 12 February 2017 to include 90 instead of 75 stocks, in an attempt to improve stability and therefore reduce risk for trackers and encourage foreign investment. Since February 2008,
972-545: The initials of its three cofounders: Chaim Salomon, Moshe Levin and Yitschak Elstein, and used camels to make deliveries. During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva and Zori. In the 1930s, Salomon, Levin, and Elstein Ltd. also founded Assia, a pharmaceutical company. Teva Pharmaceutical Industries took its present form through the efforts of Günther Friedländer and his aunt Else Kober on May 1, 1935. The original registration
1008-489: The joining of the banker Alfred Feuchtwanger as a partner in Teva, who received 33% of the shares in return for his investment. Friedländer's business philosophy opined that the pharmaceutical industry has a reliable basis in difficult economic times, since "A Jewish mother will always buy medicine for her children". In the Second World War , the company provided medicine to the allied forces and in particular to
1044-432: The link to point directly to the intended article. Retrieved from " https://en.wikipedia.org/w/index.php?title=NFTA&oldid=1044152977 " Category : Disambiguation pages Hidden categories: Short description is different from Wikidata All article disambiguation pages All disambiguation pages TA-100 Index#Constituents The index is maintained by the Tel Aviv Stock Exchange and
1080-424: The share price fell by almost half in the days following. As of September 11, 2017, Teva remained the “world's biggest seller of generics medicines.” On September 11, 2017, it was reported that they had selected Kåre Schultz as the new Teva CEO. A day later the company announced it would sell its Paragard contraceptive brand to Cooper Cos for $ 1.1 billion, with the funds being used to pay down debt. Days later
1116-651: The total positions. Specifically, women accounted for approximately 30.2% of positions within Board of Directors, a slight raise from the previous year's 27.8% figure. However, the percentage of women in general management has remained unchanged at approximately 24.8%. Teva Pharmaceutical Industries Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals ) is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs , but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to
NFTA - Misplaced Pages Continue
1152-513: The ¥40 billion purchase of a majority stake in Japanese generic drug company Taiyo Pharmaceutical Industry , a move to secure a Japan-local production facility. Teva completed the $ 934 million acquisition in July 2011. In June 2013, Teva acquired US firm MicroDose Therapeutx for $ 40 million with as much as $ 125 million being paid in regulatory and developmental milestones In 2010, Teva announced that it would build its main distribution center for
1188-699: Was completed on January 22, 2004, which marked Teva's entry into biosimilars' market. In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim , a technology park in Jerusalem . The plant received FDA approval in early 2007. Teva entered the Japanese market in 2005 and in 2008 established a generics joint venture with Kowa . In January 2006, Teva acquired its U.S. rival Ivax Corporation for $ 7.4 billion. In 2008, sales totalled $ 11.08 billion, $ 13.9 billion in 2009, and in 2010 total sales rose to $ 16.1 billion, of which
1224-402: Was granted approval by the U.S. Food and Drug Administration (FDA) for its Kfar Saba manufacturing plant. In 1995, Teva acquired Biogal Gyógyszergyár Rt. ( Debrecen , Hungary ) and acquired ICI ( Italy ). In 2000, Teva acquired Canada-based Novopharm . In October 2003, Teva announced its intentions to acquire Sicor Inc. for $ 3.4 billion. Following the announcement, the acquisition
1260-627: Was sponsored by the General Agent and Sole Distribution of medicine in Egypt and Sudan , Syria and Lebanon . Later on, Teva exported its products to the US , Soviet Union ( USSR ), health institutes in Denmark , Czechoslovakia , Persia and Burma . In 1951, Feuchtwanger initiated an initial public offering to raise capital through the newly founded Tel-Aviv Stock Exchange and Teva became
1296-479: Was under the name Teva Middle East Pharmaceutical & Chemical Works Co. Ltd. in Jerusalem, then part of Mandatory Palestine . Friedländer was a German pharmacist, botanist and pharmacognosist, who immigrated to Mandatory Palestine in 1934. The company was built with an investment of £ 4,900, which came from the family's own capital and partly from loans from other German immigrants. Capital shortage led to
#471528